Fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) and diffusion-weighted magnetic resonance imaging (DWI or DW-MRI) are tools for the diagnosis of pancreatic cancer. However, comparison of their diagnostic performance remains unknown.
Purpose
To indirectly compare the diagnostic value of DWI and FDG-PET/CT in the detection of pancreatic cancer.
Material and Methods
A literature search of PubMed, Embase, and Cochrane Library electronic databases for articles published through May 2018 yielded 875 articles. For the meta-analysis, we included 26 studies evaluating the efficacy of DWI and FDG-PET/CT for determining pancreatic cancer with a total of 1377 patients. QUADAS (Quality Assessment of Diagnostic Accuracy Studies) was used to assess the study quality. Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the receiver operating characteristic curves (AUC) with their 95% confidence intervals were calculated for each individual study.
Results
There were no significant differences between DWI and FDG-PET/CT for sensitivity, specificity, PLR, NLR, or DOR, while DWI AUC was higher than that of FDG-PET/CT for the detection of pancreatic cancer.
Conclusion
The diagnostic value of both DWI and FDG-PET/CT were comparable and, hence, both techniques seem to be equally useful tools for the diagnosis of pancreatic cancer.
SpertiCPasqualiCDecetG, et al.
F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg2005;
9:22–28; discussion 28–29.
7.
AnnovazziAPeetersMMaenhoutA, et al.
18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology2003;
125:1235–1245.
8.
DelbekeDPinsonCW.Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg2004;
11:4–10.
9.
HostenNLemkeAJWiedenmannB, et al.
Combined imaging techniques for pancreatic cancer. Lancet2000;
356:909–910.
10.
HeinrichSGoerresGWSchaferM, et al.
Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg2005;
242:235–243.
11.
MatsukiMInadaYNakaiG, et al.
Diffusion-weighed MR imaging of pancreatic carcinoma. Abdom Imaging2007;
32:481–483.
12.
MoherDLiberatiATetzlaffJ, et al.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009;
6:e1000097.
13.
WhitingPRutjesAWReitsmaJB, et al.
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol2003;
3:25.
14.
DerSimonianRLairdN.Meta-analysis in clinical trials. Control Clin Trials1986;
7:177–188.
15.
WalterSD.Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med2002;
21:1237–1256.
16.
DeeksJJHigginsJPTAltmanDG. Analyzing data and undertaking meta-analyses. In: JHigginsSEGreen, editors. Cochrane Handbook for Systematic Reviews of Interventions. 5.0.1 ed.
Oxford, UK:
The Cochrane Collaboration, 2008.
17.
HigginsJPThompsonSGDeeksJJ, et al.
Measuring inconsistency in meta-analyses. BMJ2003;
327:557–560.
18.
WoodwardM.Epidemiology: study design and data analysis. 2nd ed.
Boca Raton, FL:
Chapman and Hall/CRC, 2005.
19.
DeeksJJMacaskillPIrwigL.The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol2005;
58:882–893.
20.
SaifMWCornfeldDModarresifarH, et al.
18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients. J Gastrointestin Liver Dis2008;
17:173–178.
21.
IchikawaTErturkSMMotosugiU, et al.
High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results. AJR Am J Roentgenol2007;
188:409–414.
22.
BuchsNCBuhlerLBucherP, et al.
Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol2011;
26:657–662.
23.
CaramellaCDromainCDe BaereT, et al.
Endocrine pancreatic tumours: which are the most useful MRI sequences?Eur Radiol2010;
20:2618–2627.
24.
FarmaJMSantillanAAMelisM, et al.
PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol2008;
15:2465–2471.
25.
LemkeAJNiehuesSMHostenN, et al.
Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions–a prospective study with 104 patients. J Nucl Med2004;
45:1279–1286.
26.
KartalisNLindholmTLAspelinP, et al.
Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol2009;
19:1981–1990.
27.
KauhanenSPKomarGSeppanenMP, et al.
A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg2009;
250:957–963.
28.
KitajimaKMurakamiKYamasakiE, et al.
Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol2010;
12:452–459.
29.
LeeSSByunJHParkBJ, et al.
Quantitative analysis of diffusion-weighted magnetic resonance imaging of the pancreas: usefulness in characterizing solid pancreatic masses. J Magn Reson Imaging2008;
28:928–936.
30.
LemkeALaunFBKlaussM, et al.
Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol2009;
44:769–775.
31.
SandrasegaranKAkisikFMPatelAA, et al.
Diffusion-weighted imaging in characterization of cystic pancreatic lesions. Clin Radiol2011;
6:808–814.
32.
SchickVFranziusCBeynaT, et al.
Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging2008;
35:1775–1785.
33.
TakakuraKSumiyamaKMunakataK, et al.
Clinical usefulness of diffusion-weighted MR imaging for detection of pancreatic cancer: comparison with enhanced multidetector-row CT. Abdom Imaging2011;
36:457–462.
34.
TakanamiKHiraideTTsudaM, et al.
Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med2011;
25:501–510.
35.
TannMSandrasegaranKJenningsSG, et al.
Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin Radiol2007;
62:745–751.
36.
De RobertisRD’OnofrioMZamboniG, et al.
Pancreatic neuroendocrine neoplasms: clinical value of diffusion-weighted imaging. Neuroendocrinology2016;
103:758–770.
37.
ZhangTTWangLLiuHH, et al.
Differentiation of pancreatic carcinoma and mass-forming focal pancreatitis: qualitative and quantitative assessment by dynamic contrast-enhanced MRI combined with diffusion-weighted imaging. Oncotarget2017;
8:1744–1759.
38.
GuoCChenXWangZ, et al.
Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. Oncotarget2017;
8:42962–42973.
39.
CingarliniSOrtolaniSSalgarelloM, et al.
Role of combined 68Ga-DOTATOC and 18F-FDG positron emission tomography/computed tomography in the diagnostic workup of pancreas neuroendocrine tumors: implications for managing surgical decisions.Pancreas2017;
46:42–47.
40.
FarchioneARufiniVBriziMG, et al.
Evaluation of the added value of diffusion-weighted imaging to conventional magnetic resonance imaging in pancreatic neuroendocrine tumors and comparison with 68Ga-DOTANOC positron emission tomography/computed tomography. Pancreas2016;
45:345–354.
41.
JooILeeJMLeeDH, et al.
Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology2017;
282:149–159.
42.
ParkHJJangKMSongKD, et al.
Value of unenhanced MRI with diffusion-weighted imaging for detection of primary small (</=20 mm) solid pancreatic tumours and prediction of pancreatic ductal adenocarcinoma. Clin Radiol2017;
72:1076–1084.
43.
HuSLYangZYZhouZR, et al.
Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation. Nucl Med Commun2013;
34:533–539.
44.
JangKMKimSHKimYK, et al.
Imaging features of small (</= 3 cm) pancreatic solid tumors on gadoxetic-acid-enhanced MR imaging and diffusion-weighted imaging: an initial experience. Magn Reson Imaging2012;
30:916–925.
45.
ParkMJKimYKChoiSY, et al.
Preoperative detection of small pancreatic carcinoma: value of adding diffusion-weighted imaging to conventional MR imaging for improving confidence level. Radiology2014;
273:433–443.
46.
ToftJHaddenWJLaurenceJM, et al.
Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol2017;
92:17–23.
47.
WuLMHuJNHuaJ, et al.
Diagnostic value of diffusion-weighted magnetic resonance imaging compared with fluorodeoxyglucose positron emission tomography/computed tomography for pancreatic malignancy: a meta-analysis using a hierarchical regression model. J Gastroenterol Hepatol2012;
27:1027–1035.
48.
BaliyanVDasCJSharmaRGuptaAK.Diffusion weighted imaging: Technique and applications. World J Radiol2016;
8:785–798.
49.
ChillaGSTanCHXuCPohCL.Diffusion weighted magnetic resonance imaging and its recent trend—a survey.Quant Imaging Med Surg2015;
5:407–422.
50.
HaoJGWangJPGuYLLuML.Importance of b-value in diffusion weighted imaging for the diagnosis of pancreatic cancer. World J Gastroenterol2013;
19:6651–6655.
51.
El-ShinnawyMAZidanDZMaaroufRA.Can high-b-value diffusion weighted imaging differentiate between pancreatic cancer, mass forming focal pancreatitis and normal pancreas?Egyptian Journal of Radiology and Nuclear Medicine2013;
44:687–695.
52.
BarralMTaouliBGuiuB, et al.
Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology2014;
274:45–63.
53.
TangMYZhangXMChenTW, et al.
Various diffusion magnetic resonance imaging techniques for pancreatic cancer. World J Radiol2015;
7:424–437.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
